Exact Mass: 467.36105440000006
Exact Mass Matches: 467.36105440000006
Found 129 metabolites which its exact mass value is equals to given mass value 467.36105440000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Oxethazaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent Same as: D01152
Lucidine B
C30H49N3O (467.38754240000003)
Tiropramide
C28H41N3O3 (467.3147756000001)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AC - Synthetic antispasmodics, amides with tertiary amines D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent Tiropramide (INN) is an antispasmodic.
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z)-3-hydroxyicosa-8,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is an acylcarnitine. More specifically, it is an (11Z,14Z)-3-hydroxyicosa-11,14-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Nervonoyl Threonine
C28H53NO4 (467.39743780000003)
N-nervonoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Threonine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Semicarbazone-Stigmasta-4,22-dien-3-one,
C30H49N3O (467.38754240000003)
PC(O-14:0/O-1:0)
C23H50NO6P (467.33755700000006)
PC(O-14:0/O-1:0)[S]
C23H50NO6P (467.33755700000006)
PC(O-14:0/O-1:0)[U]
C23H50NO6P (467.33755700000006)
PC(O-15:0/0:0)
C23H50NO6P (467.33755700000006)
Tiropramide
C28H41N3O3 (467.3147756000001)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AC - Synthetic antispasmodics, amides with tertiary amines D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
Glycodeoxycholic acid
Deoxycholic acid glycine conjugate, or Deoxygcholylglycine, is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895). As a bile salt it acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic. [HMDB]
N-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine
Oxethazaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
(2S,4aS,6aS,6bR,12aS)-2,4a,6a,6b,9,9,12a-heptamethyl-10,13-dioxo-1,3,4,5,6,6a,7,8,8a,11,12,14b-dodecahydropicene-2-carboxylate
C30H43O4- (467.31611780000003)
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine
C27H49NO5 (467.36105440000006)
O-[(3R,11Z,14Z)-3-hydroxyicosadienoyl]carnitine
C27H49NO5 (467.36105440000006)
An O-acylcarnitine in which the O-acyl group is specified as (3R,11Z,14Z)-3-hydroxyicosadienoyl.
[(2R)-2-methoxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C23H50NO6P (467.33755700000006)
(14Z,17Z,20Z,23Z,26Z,29Z)-dotriacontahexaenoate
A dotriacontahexaenoate that is the conjugate base of (14Z,17Z,20Z,23Z,26Z,29Z)-dotriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-methyl-3-tetradecyl-sn-glycero-1-phosphocholine
C23H50NO6P (467.33755700000006)
2-Aminoethyl (2-hydroxy-3-octadecoxypropyl) hydrogen phosphate
C23H50NO6P (467.33755700000006)
(2-Hydroxy-3-pentadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C23H50NO6P (467.33755700000006)
N-[(8E,12E)-1,3,4-trihydroxypentadeca-8,12-dien-2-yl]tridecanamide
C28H53NO4 (467.39743780000003)
N-[(8E,12E)-1,3,4-trihydroxytetradeca-8,12-dien-2-yl]tetradecanamide
C28H53NO4 (467.39743780000003)
N-[(8E,12E)-1,3,4-trihydroxyhexadeca-8,12-dien-2-yl]dodecanamide
C28H53NO4 (467.39743780000003)
(Z)-N-[(E)-1,3,4-trihydroxyhexadec-8-en-2-yl]dodec-5-enamide
C28H53NO4 (467.39743780000003)
(Z)-N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]tridec-8-enamide
C28H53NO4 (467.39743780000003)
(Z)-N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]tetradec-9-enamide
C28H53NO4 (467.39743780000003)
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(octanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetamido-3-hydroxypentadecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Heptanoylamino)-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(nonanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Hexanoylamino)-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)dodecoxy]phosphoryl]oxyethyl-trimethylazanium
1-[(4As,5R,7S,8aR)-5-[[(1S,5S,9S,11R,13S,17R)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.02,7.013,17]heptadec-6-en-5-yl]methyl]-7-methyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
Oxetacaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent Same as: D01152
1-octadecyl-sn-glycero-3-phosphoethanolamine
C23H50NO6P (467.33755700000006)
1-pentadecyl-sn-glycero-3-phosphocholine
C23H50NO6P (467.33755700000006)
dotriacontahexaenoate
A polyunsaturated fatty acid anion that is the conjugate base of dotriacontahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
LdMePE(16:0)
C23H50NO6P (467.33755700000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
AcCa(21:1)
C28H53NO4 (467.39743780000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Glycodeoxycholic acid (monohydrate)
Glycodeoxycholic acid monohydrate is a nuclear receptor ligand. Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.
(3s,6s,9r)-5,8,11-trihydroxy-3-isopropyl-6,9-bis(2-methylpropyl)-13-pentyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
(10s)-10-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-9-methoxy-3,10-dimethyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-4,6,8(13)-trien-2-one
(2e,4e,10s)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-6-hydroxy-8-methylundeca-2,4-dienimidic acid
5,8,11-trihydroxy-9-isopropyl-6-methyl-13-(octan-2-yl)-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
1-[5-({11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl}methyl)-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
1-{4-[(1r,3as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1h-pyrrol-2-yl}-2-hydroxy-2-methylpropan-1-one
(10s)-10-{2-[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-9-methoxy-3,10-dimethyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-4,6,8(13)-trien-2-one
(2e,4e)-10-[(2r,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
1-[(4as,5r,7s,8ar)-5-{[(1s,2s,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(2e,4e,10s)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-hydroxy-8-methylundeca-2,4-dienimidic acid
(6s,9s)-3-[(2s)-butan-2-yl]-5,8,11-trihydroxy-9-isopropyl-6-methyl-13-(octan-2-yl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
1-[(4ar,5r,7s,8as)-5-{[(1s,2r,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(2e,4e)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
n-(2-{[(2s)-1-[(2s,3s)-3-dodecyl-4-oxooxetan-2-yl]nonan-2-yl]oxy}-2-oxoethyl)carboximidic acid
C27H49NO5 (467.36105440000006)
1-[(4ar,5r,7s,8as)-5-{[(1r,2r,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
1-[(4ar,5r,7s,8as)-5-{[(1s,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)